Patents Represented by Attorney Gerald V. Dahling
  • Patent number: 5455229
    Abstract: The present invention is a method for minimizing and containing injury caused when tissue is subject to ischemia and reperfusion. The method comprises administering certain derivatized tripeptide arginal compounds concurent with, or immediately after, reestablishing blood flow to the ischemic tissue. The method is particularly useful for minimizing and containing damage to the heart during evolving myocardial infarction.
    Type: Grant
    Filed: December 23, 1992
    Date of Patent: October 3, 1995
    Assignee: Eli Lilly and Company
    Inventors: Richard A. Hahn, Brian R. MacDonald, Robert T. Shuman, Gerald F. Smith
  • Patent number: 5455275
    Abstract: The present invention provides novel methods of inhibiting uterine fibroid disease and endometriosis in women comprising administering to a woman in need of treatment an effective amount of a compound of formula I ##STR1## wherein R.sup.1 and R.sup.2 may be the same or different provided that, when R.sup.1 and R.sup.2 are the same, each is a methyl or ethyl group, and, when R.sup.1 and R.sup.2 are different, one of them is a methyl or ethyl group and the other is a benzyl group, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 11, 1994
    Date of Patent: October 3, 1995
    Assignee: Eli Lilly and Company
    Inventor: Steven A. Fontana
  • Patent number: 5453502
    Abstract: The invention provides 1,3,4 substituted and bicyclic derivatives of 2-azetidinones and processes therefor. These compounds are valuable intermediates useful in the preparation of 1-carba(dethia)cephalosporin antibiotics.
    Type: Grant
    Filed: March 16, 1994
    Date of Patent: September 26, 1995
    Assignee: Eli Lilly and Company
    Inventors: James A. Aikins, Larry C. Blaszczak, Kevin P. Lund, John R. Rizzo
  • Patent number: 5453442
    Abstract: The present invention provides novel methods of lowering serum cholesterol and inhibiting smoother muscle cell proliferation, particularly restenosis, in humans, and inhibiting uterine fibroid disease and endometriosis in women comprising administering to a human/woman in need of treatment an effective amount of a compound of formula I ##STR1## wherein R is C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, halo, or trifluoromethyl;R.sup.1 and R.sup.2 each are the same or different C.sub.1 -C.sub.6 alkyl group;n is an integer from 2 to 6; andR.sup.3 and R.sup.4 each are independently C.sub.1 -C.sub.4 alkyl, or combine to form a substituent selected from the group consisting of pyrrolidino, morpholino, piperidino, piperazino, 4-(C.sub.1 -C.sub.6 alkyl)piperazino, and 4-phenyl-piperazino;or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 28, 1994
    Date of Patent: September 26, 1995
    Assignee: Eli Lilly and Company
    Inventors: Henry U. Bryant, Jeffrey A. Dodge
  • Patent number: 5451522
    Abstract: Phthalyl amidase is an enzyme previously unknown in the art that catalyzes removal of the phthalyl moiety from phthalyl-containing amides. The current invention provides DNA compounds encoding the phthalyl amidase enzyme and methods for expressing such compounds. The present invention also provides recombinant DNA vectors encoding phthalyl amidase and host cells transformed with these DNA vectors.
    Type: Grant
    Filed: July 15, 1994
    Date of Patent: September 19, 1995
    Assignee: Eli Lilly and Company
    Inventors: Stephen W. Queener, Joseph M. Zock
  • Patent number: 5451589
    Abstract: A method of inhibiting ovarian dysgenesis, delayed puberty, or sexual infantilism comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: December 21, 1993
    Date of Patent: September 19, 1995
    Assignee: Eli Lilly and Company
    Inventor: Jeffrey A. Dodge
  • Patent number: 5451590
    Abstract: A method of inhibiting sexual precocity comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: December 21, 1993
    Date of Patent: September 19, 1995
    Assignee: Eli Lilly & Co.
    Inventor: Jeffrey A. Dodge
  • Patent number: 5447941
    Abstract: A method of inhibiting pulmonary hypertensive disease comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: December 21, 1993
    Date of Patent: September 5, 1995
    Assignee: Eli Lilly and Company
    Inventor: Steven H. Zuckerman
  • Patent number: 5445941
    Abstract: The present invention relates to methods for the identification of therapeutic agents for the treatment of osteoporosis and serum lipid lowering agents. The invention relates to isolating cloning, and using nucleic acids from the promoter regions of transforming growth factor .beta. genes comprising novel regulatory elements designated "raloxifene responsive elements". The invention also encompasses eukaryotic cells containing such raloxifene responsive elements operably linked to reporter genes such that the raloxifene responsive elements modulate the transcription of the reporter genes. The invention provides methods for identifying anti-osteoporosis agents that induce transcription of genes operably linked to such raloxifene responsive elements without inducing deleterious or undesirable side effects associated with current anti-osteoporosis therapy regimens.
    Type: Grant
    Filed: June 21, 1993
    Date of Patent: August 29, 1995
    Assignee: Eli Lilly and Company
    Inventor: Na N. Yang
  • Patent number: 5445959
    Abstract: Phthalyl amidase is an enzyme previously unknown in the art that catalyzes removal of the phthalyl moiety from phthalyl-containing amides. The current invention provides said phthalyl amidase, means for producing it by culturing the natural organism from which the activity was identified, and methods for using said phthalyl amidase to remove the phthalyl moiety from phthalyl-containing amides.
    Type: Grant
    Filed: July 15, 1994
    Date of Patent: August 29, 1995
    Assignee: Eli Lilly and Company
    Inventors: Barbara S. Briggs, Milton J. Zmijewski, Jr.
  • Patent number: 5446061
    Abstract: A method of lowering serum cholesterol levels, comprising administering an effective amount of a compound having the formula ##STR1## wherein: R.sup.1 and R.sup.2 are, independently, --H, --OH, halo, --OC.sub.1 -C.sub.17 alkyl, --OC.sub.3 -C.sub.6 cycloalkyl, --O(CO)C.sub.1 -C.sub.17 alkyl, --O(CO) aryl, --O(CO)O aryl, or --OSO.sub.2 -(n-butyl or n-pentyl);R.sup.3 is ##STR2## and R.sup.4 is --H, methyl, ethyl, propyl, ethenyl or ethynyl; or a pharmaceutically acceptable salt or solvate thereof, to an animal in need of lower cholesterol levels.
    Type: Grant
    Filed: November 5, 1993
    Date of Patent: August 29, 1995
    Assignee: Eli Lilly and Company
    Inventors: Henry U. Bryant, Timothy A. Grese
  • Patent number: 5446053
    Abstract: A method of inhibiting dysfunctional uterine bleeding comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethylenemino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: December 21, 1993
    Date of Patent: August 29, 1995
    Assignee: Eli Lilly and Company
    Inventor: Patrick Keohane
  • Patent number: 5446071
    Abstract: The present invention provides methods for lowering serum cholesterol comprising administering to a mammal in need of treatment a serum cholesterol lowering amount of a compound of formula I or formula II ##STR1## wherein L is --CON< or --N<; andthe dotted line in the B-ring is an optional bond; or a pharmaceutically acceptable salt thereof; and ##STR2## wherein Q is a moiety having the formula ##STR3## L is --CON< or --N<; B is --O--, --S--, --CH.sub.2 -phenyl-O--, -phenyl-O--, or -benzyl-O--;G is a moiety which together with L forms a substituted or unsubstituted heterocyclic ring having at least one nitrogen atom or is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, lower alkynyl, (C.sub.3 -C.sub.7)cycloalkyl, halo(lower)alkyl, cyano(lower)alkyl, carboxy(lower)alkyl, (lower)alkoxycarbonyl(lower)alkyl, (C.sub.6 -C.sub.10)aryl, (C.sub.7 -C.sub.11)aryl akyl, di(lower)alkylamino(lower)alkyl, and fluoro-substituted analogs of the foregoing;Z is --O--, --S--, --CH.sub.
    Type: Grant
    Filed: November 18, 1994
    Date of Patent: August 29, 1995
    Assignee: Eli Lilly and Company
    Inventor: Timothy A. Grese
  • Patent number: 5441947
    Abstract: Wortmannin and certain of its analogs are inhibitors of restinosis.
    Type: Grant
    Filed: August 25, 1993
    Date of Patent: August 15, 1995
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey A. Dodge, Masahiko Sato
  • Patent number: 5441964
    Abstract: A method of inhibiting bone loss comprising administering to a human in need of treatment an effective amount of a substituted benzothiophene.
    Type: Grant
    Filed: October 15, 1993
    Date of Patent: August 15, 1995
    Assignee: Eli Lilly and Company
    Inventors: Henry U. Bryant, Timothy A. Grese
  • Patent number: 5441966
    Abstract: A method of inhibiting Turner's Syndrome comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: December 21, 1993
    Date of Patent: August 15, 1995
    Assignee: Eli Lilly and Company
    Inventor: Jeffrey A. Dodge
  • Patent number: 5441965
    Abstract: A method of inhibiting thrombin and its attending diseases and conditions comprising administering to a human in need of treatment an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidino, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: December 21, 1993
    Date of Patent: August 15, 1995
    Assignee: Eli Lilly and Company
    Inventors: Daniel J. Sall, Gerald F. Smith
  • Patent number: 5439923
    Abstract: A method of inhibiting acne or seborrhea comprising administering to a human in need of treatment an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: December 21, 1993
    Date of Patent: August 8, 1995
    Assignee: Eli Lilly and Company
    Inventor: George J. Cullinan
  • Patent number: 5434166
    Abstract: A method of inhibiting demyelinating or dysmyelinating diseases or their symptoms comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: August 22, 1994
    Date of Patent: July 18, 1995
    Assignee: Eli Lilly and Company
    Inventor: Andrew L. Glasebrook
  • Patent number: 5434259
    Abstract: Provided is a process for isolating cefaclor from an acylation reaction mixture by adding anthraquinone-1,5-disulfonic acid to the mixture. The acid highly selectively precipitates with cefaclor so that isolation and recovery is streamlined.
    Type: Grant
    Filed: February 5, 1993
    Date of Patent: July 18, 1995
    Assignee: Eli Lilly and Company
    Inventor: John P. Gardner